Johannes Dunkel1, Samuli Vaittinen2, Petri Koivunen3, Jussi Laranne4, Markus J Mäkinen5, Satu Tommola6, Heikki Irjala7. 1. Medicity Research Laboratory and Turku Doctoral Programme of Molecular Medicine University of Turku. 2. the Department of Pathology University of Turku and Turku University Hospital Turku. 3. the Research Center for Otorhinolaryngology and Ophthalmology, University of Oulu and Department of Otorhinolaryngology and Medical Research Center Oulu, Oulu University Hospital. 4. the Department of Otorhinolaryngology Head and Neck Surgery Tampere University Hospital. 5. the Department of Pathologyand Medical Research Center Oulu, Oulu University Hospital and University of Oulu Oulu. 6. the Department of Pathology University of Tampere and Tampere University Hospital Tampere Finland. 7. the Department of Otorhinolaryngology Head and Neck Surgery Turku University Hospital.
Abstract
OBJECTIVES/HYPOTHESIS: No biomarkers are used to estimate the prognosis in oral cavity squamous cell carcinoma (OSCC). In our previously published work, we have reported the prognostic value of CD44 and hypoxia inducible factor (HIF)-1α in patients with stage I disease. STUDY DESIGN: In this study, we tested our previous observations in a larger cohort. We also studied the predictive value of common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 in this material. METHODS: CD44, HIF1α, and CLEVER-1 were immunohistochemically analyzed in paraffin-embedded tissue material of stage I OSCC patients treated at three Finnish university hospitals. Microscopy results were correlated with OSCC outcome. RESULTS: As in our pilot study, the CD44lowHIF1αhigh signature was associated with poorer disease-free survival. Clear correlations between CLEVER-1 expression and clinical outcome were not evident. CONCLUSION: Our results suggest that immunohistochemistry of CD44 and HIF1α may be useful in identification of patients with poor prognoses. These parameters could be used to select the optimal treatment modalities for stage I OSCC patients. LEVEL OF EVIDENCE: 2b.
OBJECTIVES/HYPOTHESIS: No biomarkers are used to estimate the prognosis in oral cavity squamous cell carcinoma (OSCC). In our previously published work, we have reported the prognostic value of CD44 and hypoxia inducible factor (HIF)-1α in patients with stage I disease. STUDY DESIGN: In this study, we tested our previous observations in a larger cohort. We also studied the predictive value of common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 in this material. METHODS:CD44, HIF1α, and CLEVER-1 were immunohistochemically analyzed in paraffin-embedded tissue material of stage I OSCC patients treated at three Finnish university hospitals. Microscopy results were correlated with OSCC outcome. RESULTS: As in our pilot study, the CD44lowHIF1αhigh signature was associated with poorer disease-free survival. Clear correlations between CLEVER-1 expression and clinical outcome were not evident. CONCLUSION: Our results suggest that immunohistochemistry of CD44 and HIF1α may be useful in identification of patients with poor prognoses. These parameters could be used to select the optimal treatment modalities for stage I OSCC patients. LEVEL OF EVIDENCE: 2b.
Authors: Annika Algars; Heikki Irjala; Samuli Vaittinen; Heikki Huhtinen; Jari Sundström; Marko Salmi; Raija Ristamäki; Sirpa Jalkanen Journal: Int J Cancer Date: 2011-11-08 Impact factor: 7.396
Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702
Authors: Antoine E Melkane; Anne Auperin; Patrick Saulnier; Ludovic Lacroix; Philippe Vielh; Odile Casiraghi; Issam Msakni; Françoise Drusch; Stéphane Temam Journal: Head Neck Date: 2013-06-01 Impact factor: 3.147
Authors: Heikki Irjala; Kalle Alanen; Reidar Grénman; Päivi Heikkilä; Heikki Joensuu; Sirpa Jalkanen Journal: Cancer Res Date: 2003-08-01 Impact factor: 12.701
Authors: Falk Wehrhan; Maike Büttner-Herold; Peter Hyckel; Patrick Moebius; Raimund Preidl; Luitpold Distel; Jutta Ries; Kerstin Amann; Christian Schmitt; Friedrich W Neukam; Manuel Weber Journal: BMC Cancer Date: 2014-07-21 Impact factor: 4.430